ArticleFrontiers in pharmacology2025

Cost-effectiveness analysis of eight first-line treatments for metastatic hormone-sensitive prostate cancer in China.

Zhou Han et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.